<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874430</url>
  </required_header>
  <id_info>
    <org_study_id>16D.317</org_study_id>
    <nct_id>NCT02874430</nct_id>
  </id_info>
  <brief_title>Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer</brief_title>
  <official_title>A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well metformin hydrochloride works together with doxycycline
      in treating patients with localized breast or uterine cancer. Metformin hydrochloride may
      stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
      Doxycycline may stop the growth of bacteria by keeping them from making proteins and
      minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving
      metformin hydrochloride together with doxycycline may be a better way in treating patients
      with localized breast or uterine cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if treatment with a combination of metformin and doxycycline can increase the
      percentage of cells that express Caveolin-1 in the cancer associated fibroblasts of patients
      with breast, or uterine, and cervical cancers.

      SECONDARY OBJECTIVES:

      I. To determine the effect of metformin and doxycycline treatment on the percentage of cells
      that express monocarboxylate transporter (MCT)4 in cancer associated fibroblasts and MCT1 and
      transporter of outer mitochondrial membrane (TOMM)20 in the cancer cells of breast and
      uterine cancer patients.

      II. To assess safety and tolerability of metformin and doxycycline treatment in subjects with
      breast and uterine cancer.

      III. To determine the relationship of the percentage of stromal cells expressing caveolin
      (CAV)1 or MCT4 and tumor cells that express MCT1 and TOMM20 at baseline and after treatment
      with metformin and doxycycline with the percentage of cells expressing estrogen receptor (ER)
      and progesterone receptor (PR) for breast and uterine samples and human epidermal growth
      factor (HER)2 in breast cancer samples.

      TERTIARY OBJECTIVES:

      I. To assess the effect of combined metformin and doxycycline therapy on the metabolic
      profile of cancer cells and stroma using mass spectroscopy imaging (MSI) on paired samples,
      comparing metabolite profiles in the pre-metformin and post-metformin tumor sample.

      II. To assess, when possible, the impact of a patient's nutritional status, estimated using 3
      day dietary recall versus caloric needs as calculated by the Harris-Benedict equation on the
      baseline and net change in CAV1 III. To assess the effect of combined metformin and
      doxycycline therapy on oncomiR micro ribonucleic acid (RNA) (miR-21) after intervention.

      IV. To assess the effect of combined metformin and doxycycline therapy on adipokines and the
      insulin-like growth factor (IGF)-1/insulin signaling pathways through assessment of serum
      triglycerides, IGF-1, IGF-binding protein (BP)3, erythrocyte sedimentation rate (ESR),
      adiponectin, leptin, IGF-1 receptor (R), exosome evaluation, metabolomics profile, and
      microRNA expression profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the percent of stromal cells expressing Caveolin-1 (CAV1) at an intensity of 1+ or greater assessed by immunohistochemistry</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Within-patient change in immunohistochemistry scores will be analyzed using the Wilcoxon signed-rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>At 30 days after last dose of metformin and doxycycline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percent of stromal cells expressing express Monocarboxylate Transporter 4 (MCT4) in the cancer cells</measure>
    <time_frame>Baseline up to week 5</time_frame>
    <description>Analysis will be performed separately in breast and uterine cancer patients. Evaluated using Aperio analyses of expression intensity with previously validated algorithms. Analysis will be performed using the Wilcoxon signed-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percent of tumor cells that express Monocarboxylate Transporter 1 (MCT1) and Transporter of Outer Mitochondrial Membrane 20 (TOMM20) in the cancer cells</measure>
    <time_frame>Baseline up to week 5</time_frame>
    <description>Analysis will be performed separately in breast and uterine cancer patients. Evaluated using Aperio analyses of expression intensity with previously validated algorithms. Analysis will be performed using the Wilcoxon signed-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of stromal cells expressing Caveolin-1 (CAV1) or Monocarboxylate Transporter 4 (MCT4)</measure>
    <time_frame>Baseline up to week 5</time_frame>
    <description>Assessed in relation to the percentage of cells expressing Estrogen Receptor (ER) and Progesterone Receptor (PR) for breast and uterine samples and Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of tumor cells that express Monocarboxylate Transporter 1 (MCT1) and Transporter of Outer Mitochondrial Membrane 20 (TOMM20)</measure>
    <time_frame>Baseline up to week 5</time_frame>
    <description>Assessed in relation to the percentage of cells expressing Estrogen Receptor (ER) and Progesterone Receptor (PR) for breast and uterine samples and Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>Up to 12 months post last dose of metformin and doxycycline</time_frame>
    <description>Will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 12 months post last dose of metformin and doxycycline</time_frame>
    <description>Will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 12 months post last dose of metformin and doxycycline</time_frame>
    <description>Up to 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Endometrial Clear Cell Adenocarcinoma</condition>
  <condition>Endometrial Serous Adenocarcinoma</condition>
  <condition>Uterine Corpus Cancer</condition>
  <condition>Uterine Corpus Carcinosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (metformin hydrochloride, doxycycline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (metformin hydrochloride, doxycycline)</arm_group_label>
    <other_name>1,1-Dimethylbiguanide Hydrochloride</other_name>
    <other_name>1115-70-4</other_name>
    <other_name>91485</other_name>
    <other_name>Cidophage</other_name>
    <other_name>Dimefor</other_name>
    <other_name>Glifage</other_name>
    <other_name>Glucoformin</other_name>
    <other_name>Glucophage</other_name>
    <other_name>N,N-Dimethylimidodicarbonimidic Diamide Monohydrochloride</other_name>
    <other_name>Riomet</other_name>
    <other_name>Siofor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (metformin hydrochloride, doxycycline)</arm_group_label>
    <other_name>17086-28-1</other_name>
    <other_name>Doxycycline Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be eligible for participation in this trial, the subject must:

          1. Diagnosis of localized breast or uterine cancer that is either biopsy proven or
             suspected based on history, physical, and or radiographic findings, and who are
             planned for definitive resection of the tumor without the use of neoadjuvant
             chemotherapy or radiation therapy at TJUH are eligible to participate.

          2. Subjects must be â‰¥ 18 years of age at time of consent.

          3. Subjects must be newly diagnosed or suspected to have breast, uterine (endometrial
             cancer with histologies including endometrioid, serous, clear cell, and
             carcinosarcoma) or cervical cancer.

          4. Patient must be able to swallow pills.

          5. Patients with serum creatinine levels less than 1.5 mg/dL.

          6. Women of child bearing potential must have a negative urine or blood pregnancy test
             within 14 days of study enrollment.

          7. Informed Consent: All subjects must be able to comprehend and sign a written informed
             consent document.

          8. ECOG Performance status &lt;1

        Exclusion Criteria:

        The subject must be excluded from participating in the trial if the subject:

          1. Subjects that do not have a baseline tumor specimen/biopsy prior to starting study
             medications.

             a. Tumor specimens do not need to be at Jefferson at time of eligibility
             determination. Tumor specimens held at outside institutions are not a reason for
             exclusion. Samples from outside institutions should be requested for analysis of
             pre-treatment tumor vs post-treatment tumor.

          2. Received any prior cancer therapy for the breast or uterine cancer that is being
             resected, including progesterone therapy for endometrial cancer patients.

             a. Patients may have had prior therapy for other contra-lateral breast cancer.

          3. Subjects who are pregnant or breastfeeding or may become pregnant during metformin and
             doxycycline administration.

          4. Subjects on metformin or doxycycline for any reason during the preceding 4 weeks.

          5. Diabetic subjects that are managed by taking metformin or insulin.

          6. Subjects who have received iodinated contrast dye must wait 12 hours prior to starting
             Metformin. If a CT scan with contrast is scheduled after screening and consent, the
             metformin cannot be taken until after the CT with contrast has been completed and they
             have waited 12 hours.

          7. Patients with serum creatinine level greater than 1.5 mg/dL.

          8. Patients with history of lactic or any other metabolic acidosis.

          9. Patients with history of congestive heart failure stage III or greater.

         10. Patients scheduled for definitive cancer surgical resection less than 7 days from
             beginning of study drug administration or greater than 6 weeks from beginning study
             drug administration.

         11. Patients with history of hepatic dysfunction or hepatic disease and abnormal liver
             function tests defined as AST, ALT, Alk Phos, and or total bilirubin greater than 2.5
             times the upper limit of normal.

             a. Patients who have a history of hepatic dysfunction or hepatic disease and normal
             liver function tests will be eligible to participate.

         12. Patients with a current history (in the past 30 days) of heavy drinking which is
             defined in accordance with CDC definition as more than 8 drinks per week for women and
             more than 15 drinks per week for men. A standard drink contains .6 ounces of pure
             alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer,
             8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a &quot;shot&quot; of 80-proof
             distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). While on study,
             patients should limit their alcohol consumption to no more than 8 drinks per week for
             women and no more than 15 drinks per week for men. Patients who feel they cannot
             comply with this recommendation are not eligible.

         13. Prior allergic reaction to metformin, doxycycline, or any other tetracycline
             antibiotic in the past.

         14. Patient is on medications that are contraindicated with metformin or doxycycline under
             current FDA recommendations. The following is a list of medications identified as
             class D (consider therapy modification) when treatment with metformin or doxycycline
             is considered:

               -  Class D:

                    -  Bismuth Subsalicylate

                    -  Cimetidine

                    -  Iodinated contrast agents

                    -  Somatropin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Johnson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Johnson, MD, PhD</last_name>
    <phone>215-955-8874</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Johnson, MD, PhD</last_name>
      <phone>215-955-8874</phone>
    </contact>
    <investigator>
      <last_name>Adam Berger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Tsangaris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Lazar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norman Rosenblum, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Leiby, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madalina Tuluc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Chan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ubaldo Martinez Outschoorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Simone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

